As per the research report released by Spearhead Acuity Business Research & Consulting, emerging markets such as Brazil, India, China, Middle-East and parts of South-East Asia may erode the neurodiagnostic and monitoring devices market of North America, which is currently the global market leader with 44% share. The Asia-Pacific region had captured 16.7% market share in 2014 and is forecasted to capture 18.3% market share by 2019. Continuous healthcare investments and increasing number of hospitals with neurospecialty clinics have derived the growth of the market. Another factor contributing to the growth is the high level of awareness about sleep diagnostics. There are multiple manufacturers in North America and Europe; however, there are more manufacturers of these devices in Asia-Pacific. It is estimated that there are over 20 million epilepsy patients in the Asia-Pacific region. The largest product segment is the magnetoencephalography devices (MEG).
Emerging economies such as Brazil may affect North American neurodiagnostic devices market
GHI Analysis1 min read
GHI Analysis
The leading source of MedTech market intelligence in Latin America. Verified data and competitor insights across the key markets in the region. At GHI, we turn hospital data into strategic actions. Our insights help healthcare companies expand by providing accurate, up-to-date information on hospital infrastructure in LATAM and Asia.
Related Posts
Análisis GHI
5 Key Growth Areas in Brazil’s Healthcare Market for 2021
5 Key Growth Areas in Brazil’s Healthcare Market for 2021
We combine data from GHI’s resources (primarily HospiScope) and outside sources to highlight some healthcare…
GHI Analysisdiciembre 4, 2020
Análisis GHI
Latin America’s Top 4 Medical Tourism Markets
Latin America’s Top 4 Medical Tourism Markets
As the market has continued to grow and evolve, however, people are traveling south for…
GHI Analysisseptiembre 22, 2017
News
Mexico: IMSS launches bidding of medicines: USD 3.09 billion (MXN 55 billion)
Mexico: IMSS launches bidding of medicines: USD 3.09 billion (MXN 55 billion)
The Mexican Social Security Institute (IMSS), started the bidding process for the period 2017-2018 for…
GHI Analysisagosto 28, 2017